08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
If the coronavirus pandemic continues to spread in the United States as it has in other countries, d...
Read More >
The 1099 independent contractor model can be the ideal setup for some employers and workers. However...
Read More >
Construction has long been a difficult industry for women, minorities, and LGBT workers as old ideas...
Read More >
The Department of Transportation’s (DOT) recent notice on the use of cannabidiol (CBD) products ser...
Read More >
Seyfarth Synopsis: On December 19, 2019, the U.S. Treasury issued final Qualified Opportunity Zone r...
Read More >
On February 1, 2021, the Federal Trade Commission (FTC) announced its revised annual threshold that ...
Read More >